PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR -ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1. HEPATITIS C: WEEK 4 INTERIM RESULTS (vol 48, pg 4, 2008)

被引：0
|
作者：
Forns, X. [1 ]
Marcellin, P. [2 ]
Goeser, T. [3 ]
Ferenci, P. [4 ]
Nevens, F. [5 ]
Carosi, G. [6 ]
Drenth, J. P. [7 ]
De Backer, K. [8 ]
van Heeswijk, R. [8 ]
Vangeneugden, T. J. [8 ]
Picchio, G. [9 ]
Beumont-Mauviel, M. [8 ]
机构：
[1] Univ Barcelona, Liver Unit, Barcelona, Spain
[2] Hop Beaujon, Clichy, France
[3] Klinikum Univ Koln, Cologne, Germany
[4] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria
[5] Univ Hosp Gasthuisberg, Dept Hepatol, B-3000 Louvain, Belgium
[6] Univ Brescia, Clin Infect & Trop Dis, Brescia, Italy
[7] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[8] Tibotec BVBA, Mechelen, Belgium
[9] Tibotec Inc, Yardley, PA USA
来源：
HEPATOLOGY | 2008年 / 48卷 / 06期
关键词：
D O I：
10.1002/hep.22702
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：2093 / 2093
页数：1
相关论文
共 50 条
  • [41] Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1.
    Berg, T
    von Wagner, M
    Hinrichsen, H
    Heintges, T
    Buggisch, P
    Goeser, T
    Rasenack, J
    Pape, GR
    Schmidt, WE
    Kallinowski, B
    Klinker, H
    Spengler, U
    Klapperich, B
    Popescu, M
    Zeuzem, S
    HEPATOLOGY, 2003, 38 (04) : 317A - 317A
  • [42] TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY
    Manns, M.
    Muir, A.
    Adda, N.
    Jacobson, I.
    Afdhal, N.
    Heathcote, J.
    Zeuzem, S.
    Reesink, H.
    Terrault, N.
    Bsharat, M.
    George, S.
    McHutchison, J.
    Di Bisceglie, A.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S379 - S379
  • [43] Peginterferon-Alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment (vol 131, pg 451, 2006)
    Sanchez-Tapias, J. M.
    Diago, M.
    Escartin, P.
    Enriquez, J.
    Romero-Gomez, M.
    Barcena, R.
    Crespo, J.
    Andrade, R.
    Martinez-Bauer, E.
    Perez, R.
    Testillano, M.
    Planas, R.
    Sola, R.
    Garcia-Bengoechea, M.
    Garcia-Samaniego, J.
    Munoz-Sanchez, M.
    Moreno-Otero, R.
    GASTROENTEROLOGY, 2006, 131 (04) : 1363 - 1363
  • [44] Albumin interferon alfa-2b dosed at Q2W or Q4W intervals demonstrates comparable week 12 efficacy response in IFN naive, genotype-1 rapid viral responders
    Neumann, A. U.
    Rozenberg, L.
    Zeuzem, S.
    Benhamou, Y.
    McHutchison, J.
    Pulkstenis, E.
    Subramanian, M.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S236 - S236
  • [45] Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Kwo, Paul Y.
    Lawitz, Eric J.
    McCone, Jonathan
    Schiff, Eugene R.
    Vierling, John M.
    Pound, David
    Davis, Mitchell N.
    Galati, Joseph S.
    Gordon, Stuart C.
    Ravendhran, Natarajan
    Rossaro, Lorenzo
    Anderson, Frank H.
    Jacobson, Ira M.
    Rubin, Raymond
    Koury, Kenneth
    Pedicone, Lisa D.
    Brass, Clifford A.
    Chaudhri, Eirum
    Albrecht, Janice K.
    LANCET, 2010, 376 (9742): : 705 - 716
  • [46] Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (vol 376, pg 705, 2010)
    Kwo, P. Y.
    Lawitz, E. J.
    McCone, J.
    LANCET, 2010, 376 (9748): : 1224 - 1224
  • [47] SAFETY AND EFFICACY OF MK-5172 PLUS PEGINTERFERON ALFA-2b AND RIBAVIRIN (PR) IN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G)1 INFECTION
    Hezode, C.
    Bruno, S.
    Jacobson, I.
    Serfaty, L.
    Kwo, P.
    Zhou, A.
    Gilbert, C.
    Hwang, P.
    Wahl, J.
    Robertson, M. N.
    Mobashery, N.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S500 - S500
  • [48] EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C
    Poordad, F.
    Lawitz, E.
    Pozza, R.
    Shiffman, M.
    Bacon, B.
    Godofsky, E.
    Halliman, D.
    Heise, J.
    Chun, E.
    Hammond, J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S8 - S8
  • [49] IL28B-BASED MODEL FOR PREDICTION OF WEEK 4 VIRAL RESPONSE IN PEGINTERFERON-alfa2a+RIBAVIRIN TREATED HEPATITIS C GENOTYPE 1&4. FINAL REPORT WEEK 4 OPTIM STUDY
    Romero-Gomez, M.
    de Cuenca, B.
    Baeyens, E.
    Garcia-Samaniego, J.
    Salmeron, J.
    Alonso, M. D. M.
    Buenestado, J.
    Munoz, R.
    Diago, M.
    Garcia, A.
    Minguez, C.
    Morano, L.
    Giron, J. A.
    Gonzalez-Garcia, J.
    Crespo, J.
    Planas, R.
    Turnes, J.
    Calleja, J. L.
    Sola, R.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S368 - S368
  • [50] VIRAL RESPONSES IN AFRICAN-AMERICANS, LATINOS AND CAUCASIANS IN THE US PHASE 2 STUDY (PROVE1) OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAME GENOTYPE 1-INFECTED SUBJECTS WITH HEPATITIS C
    Muir, Andrew J.
    Lawitz, Eric J.
    McHutchison, John G.
    Gordon, Stuart C.
    Jacobson, Ira M.
    Adiwijaya, Bambang S.
    Bengtsson, Leif
    McNair, Lindsay
    Rodriguez-Torres, Maribel
    HEPATOLOGY, 2008, 48 (04) : 1131A - 1132A
12345